Touch Medical Media coverage of data presented at EADV 2022:
ADvocate 1 (NCT04146363) and ADvocate 2 (NCT04178967) are phase 3, randomised, double-blind, placebo-controlled trials, investigating lebrikizumab monotherapy in moderate to severe atopic dermatitis. touchIMMUNOLOGY caught up with Prof. Gil Yosipovitch (Miller School of Medicine, University of Miami, Miami, FL, USA) around the ADvocate 1 and ADvocate 2 phase 3 studies and the findings from his analysis of these studies presented at EADV, focusing on improvement in itch severity.
The abstract ‘Lebrikizumab monotherapy improved itch in adults and adolescents with moderate to severe atopic dermatitis in two phase 3 trials.‘ (Abstract number: 765) was presented at EADV 2022, 7-10 September, 2022.
Questions
- What is the impact of itch on quality of life in atopic dermatitis? (0:21)
- Could you give us a brief overview of the ADvocate 1 and ADvocate 2 studies and their primary findings? (0:38)
- What were the findings in terms of itch severity, and how clinically meaningful was this change? (1:26)
- What will be the clinical impact of these findings? (2:51)
Disclosures: Gil Yosipovitch discloses consulting for Sanofi Regeneron, Eli Lilly, Galderma, Sanofi, Kiniksa, Trevi, Escient and Pfizer; receiving grant/ research support from Sanofi Regenron, Eli Lilly, Novartis, Pfizer, Escient; serving on advisory boards for Sanofi Regeneron, Eli Lilly, Galderma, Sanofi, Kiniksa, Trevi, Escient and Pfizer; receiving honoraria from Sanofi Regeneron, Eli Lilly, Galderma, Sanofi, Kiniksa, Trevi, Escient, Pfizer and Novartis.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
This content was developed by Touch Medical Media and is not affiliated with the European Academy of Dermatology & Venereology (EADV) or the congress.
